942296-83-5Relevant academic research and scientific papers
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors
Cullen, Matthew D.,Cheung, York-Fong,Houslay, Miles D.,Hartman, Tracy L.,Watson, Karen M.,Buckheit Jr., Robert W.,Pannecouque, Christophe,De Clercq, Erik,Cushman, Mark
, p. 1530 - 1533 (2008)
The alkenyldiarylmethanes (ADAMs) are currently being investigated as non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs) of potential value in the treatment of HIV infection and AIDS. During the course of these studies, a number of ADAM analog
Methylenedisalicylic acid derivatives: New PTP1B inhibitors that confer resistance to diet-induced obesity
Shrestha, Suja,Bhattarai, Bharat Raj,Chang, Kyung Ja,Lee, Keun-Hyeung,Cho, Hyeongjin
, p. 2760 - 2764 (2008/02/04)
Methylenedisalicylic acid derivatives were synthesized and their inhibitory activities against protein tyrosine phosphatases (PTPases) examined. Two of the compounds, 8 and 9, showed Ki values of 9.4 and 6.3 μM against PTP1B, 4- and 7-fold lower values compared to those against TC-PTP. They were reversible and slow-binding inhibitors against PTP1B. When compound 8 was fed to a mouse model, the weight gain and adipocyte fat storage induced by a high-fat-diet were significantly suppressed.
